ClinicalTrials.gg
RecruitingNCT07722910Updated Jul 28, 2026

Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma

An observational study in Neovascular Glaucoma and Type 2 Diabetes, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Qilu Hospital of Shandong University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
98
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questions it aims to answer are:

  • Does iris blood flow fraction at six pupillary quadrants differ significantly among people with different stages of type 2 diabetic eye complications?
  • Are there quadrant-specific and gender-based differences in iris microcirculation changes caused by diabetic eye diseases? If there is a comparison group: Researchers will compare iris blood flow data from four groups (healthy controls, T2DM without DR, T2DM with DR, T2DM with DR + NVG) to see how iris blood circulation changes as diabetic eye conditions get worse, and test whether iris blood flow indicators can help identify patients with neovascular glaucoma.

Participants will complete the following tasks:

  • Provide basic personal information, past medical history and recent laboratory test results from their routine medical records;
  • Receive a painless, non-invasive iris OCTA eye scan to capture iris blood flow images at six quadrants around the pupil.
02

Conditions studied

  • Neovascular Glaucoma
  • Type 2 Diabetes

Keywords

  • Diabetic retinopathy
  • Neovascular glaucoma
  • Optical coherence tomography angiography
  • Iris vessel density
  • Anti-VEGF therapy
03

In context

Glaucoma, Neovascular

39 studies on the registry are indexed under Glaucoma, Neovascular; 5 are open to participants now.

Browse Glaucoma, Neovascular studies →

Lead sponsor

Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of adults aged 18 years or older of all genders who visit Qilu Hospital, Shandong University. Participants are divided into four groups: healthy volunteers without type 2 diabetes mellitus, patients with type 2 diabetes without fundus lesions, patients with type 2 diabetes combined with diabetic retinopathy, and patients with type 2 diabetic retinopathy complicated by neovascular glaucoma. All subjects have clear consciousness and can cooperate to complete iris OCTA examination, with no contraindications specified in the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years of age, regardless of gender, with or without type 2 diabetes mellitus and its associated ocular complications; clear consciousness, capable of cooperating with iris OCTA examination (able to stabilize the head to guarantee successful acquisition and interpretable images).
  • Voluntary participation in this study with signed written .
  • No history of intraocular surgery in the examined eye (including cataract surgery, glaucoma filtering surgery, retinal surgery, etc.).
  • General physical conditions: No acute disease episodes within the recent 3 months (such as acute myocardial infarction, stroke, diabetic ketoacidosis); no severe liver or renal dysfunction ( and AST ≤ 2 times the , serum creatinine ≤ 133 μmol/L).

Exclusion criteria

Exclusion Criteria:

  • The studied eye suffers from other ocular diseases that may interfere with examination results apart from the disorders specified in Criterion 1 of the inclusion criteria (e.g., uveitis, retinal vein occlusion, high myopia-related fundus lesions, etc.); invasive ocular treatments were administered to the studied eye within the past 6 months (e.g., retinal laser photocoagulation, intravitreal injection, etc.).
  • Subjects complicated with type 1 diabetes mellitus, gestational diabetes mellitus or other specific types of diabetes mellitus; those with diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or hematological diseases (e.g., leukemia, aplastic anemia); individuals who have taken medications affecting ocular microcirculation (e.g., alprostadil, nitrates) within the past 3 months and are unable to discontinue such drugs.
  • Subjects with severe head tremors and inability to maintain a fixed posture during examination, resulting in substandard OCTA image quality (interpretable area \< 80%); those with mental disorders or cognitive dysfunction who fail to understand and cooperate with the examination procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
98 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes

Groups and cohorts

  • Control

    Patients without type 2 diabetes

  • NDR

    Patients with type 2 diabetes but without diabetic retinopathy

  • DR

    Patients with type 2 diabetic retinopathy

  • DR+NVG

    Patients with type 2 diabetic retinopathy and neovascular glaucoma

06

What researchers measure

Primary outcomes

  1. Iris vessel density

    Iris vessel density measured by Optical Coherence Tomography Angiography(OCTA)

    Time frame: Enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Elkholy RE, El Sharkawy AM, Hantash HI, Elaskary EM, Shafik HM, Nawar AE, Almokadem HA. Evaluation of Retinal Microvascular Changes in Juvenile Systemic Lupus Erythematosus Patients Using Optical Coherence Tomography Angiography. Ocul Immunol Inflamm. 2026 Jul 11:1-8. doi: 10.1080/09273948.2026.2690413. Online ahead of print. PubMed 42435066 ↗
  • Zhang G, Chen W, Chen H, Lin J, Cen LP, Xie P, Zheng Y, Ng TK, Brelen ME, Zhang M, Pang CP. Risk factors for diabetic retinopathy, diabetic macular edema, and sight-threatening diabetic retinopathy. Asia Pac J Ophthalmol (Phila). 2024 May-Jun;13(3):100067. doi: 10.1016/j.apjo.2024.100067. Epub 2024 May 13. PubMed 38750958 ↗
  • Qi Z, Si Y, Feng F, Zhu J, Yang X, Wang W, Zhang Y, Cui Y. Analysis of retinal and choroidal characteristics in patients with early diabetic retinopathy using WSS-OCTA. Front Endocrinol (Lausanne). 2023 May 24;14:1184717. doi: 10.3389/fendo.2023.1184717. eCollection 2023. PubMed 37293481 ↗
  • Lidder AK, Paranjpe V, Lauter AJ. Management of Neovascular Glaucoma. Int Ophthalmol Clin. 2023 Oct 1;63(4):167-183. doi: 10.1097/IIO.0000000000000480. Epub 2023 Sep 27. No abstract available. PubMed 37755450 ↗
  • Kalogeropoulos D, Moussa G, Sung VC, Pappa C, Kalogeropoulos C. Neovascular Glaucoma: An Update. Klin Monbl Augenheilkd. 2023 Mar;240(3):305-315. doi: 10.1055/a-1956-9348. Epub 2022 Nov 27. PubMed 36436509 ↗
  • Barth T, Helbig H. [Diabetic retinopathy]. Klin Monbl Augenheilkd. 2021 Oct;238(10):1143-1159. doi: 10.1055/a-1545-9927. Epub 2021 Aug 11. German. PubMed 34380155 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This study contains sensitive personal medical records and iris imaging data of participants, which involves patient privacy protection. There is no plan to upload individual participant data to public databases or share raw IPD with external researchers. All individual-level identifiable data will not be shared externally to comply with hospital ethics and privacy regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jul 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
May 23, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722910
Responsible party
YutingZhang (Principal Investigator, Qilu Hospital of Shandong University) — Principal investigator
First posted
Jul 23, 2026
Start date
May 23, 2026
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Yuting Zhang, Doctor of Medicine
Contact
zhangyt_7085@163.com
+86 185-6008-8152
Hui Guo, Doctor of Medicine
Contact
guohui@sdu.edu.cn
+86 185-6008-7106

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion